Myeloproliferative neoplasm laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Shyam Patel (talk | contribs) |
||
| (7 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Myeloproliferative disease}} | {{Myeloproliferative disease}} | ||
{{CMG}} {{AE}} {{MJK}} | {{CMG}} {{AE}} {{MJK}} {{shyam}} | ||
==Overview== | ==Overview== | ||
Laboratory findings | Laboratory findings associated with the diagnosis of myeloproliferative neoplasm include [[leukocytosis]], [[thrombocytopenia]], and [[anemia]]. | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
Laboratory findings associated with myeloproliferative neoplasm include:<ref name="cancer.ca">Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab</ref><ref>{{Cite journal | Laboratory findings associated with myeloproliferative neoplasm include:<ref name="cancer.ca">Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab</ref><ref>{{Cite journal | ||
| Line 16: | Line 16: | ||
| doi = 10.1309/AJCPUN89CXERVOVH | | doi = 10.1309/AJCPUN89CXERVOVH | ||
| pmid = 19605820 | | pmid = 19605820 | ||
}}</ref><ref name="Sánchez-MuñozAlvarez-Twose2011">{{cite journal|last1=Sánchez-Muñoz|first1=Laura|last2=Alvarez-Twose|first2=Ivan|last3=García-Montero|first3=Andrés C|last4=Teodosio|first4=Cristina|last5=Jara-Acevedo|first5=María|last6=Pedreira|first6=Carlos E|last7=Matito|first7=Almudena|last8=Morgado|first8=Jose Mario T|last9=Sánchez|first9=Maria Luz|last10=Mollejo|first10=Manuela|last11=Gonzalez-de-Olano|first11=David|last12=Orfao|first12=Alberto|last13=Escribano|first13=Luis|title=Evaluation of the WHO criteria for the classification of patients with mastocytosis|journal=Modern Pathology|volume=24|issue=9|year=2011|pages=1157–1168|issn=0893-3952|doi=10.1038/modpathol.2011.84}}</ref><ref>{{cite book |author=Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates|title=Dacie & Lewis Practical Haematology |publisher=W B Saunders |location=London |year= |pages= |isbn=0-443-06377-X |pages=586}}</ref><ref name="O'Brien2004">{{cite journal|last1=O'Brien|first1=S.|title=Chronic Myelogenous Leukemia and Myeloproliferative Disease|journal=Hematology|volume=2004|issue=1|year=2004|pages=146–162|issn=1520-4391|doi=10.1182/asheducation-2004.1.146}}</ref> | }}</ref><ref name="Sánchez-MuñozAlvarez-Twose2011">{{cite journal|last1=Sánchez-Muñoz|first1=Laura|last2=Alvarez-Twose|first2=Ivan|last3=García-Montero|first3=Andrés C|last4=Teodosio|first4=Cristina|last5=Jara-Acevedo|first5=María|last6=Pedreira|first6=Carlos E|last7=Matito|first7=Almudena|last8=Morgado|first8=Jose Mario T|last9=Sánchez|first9=Maria Luz|last10=Mollejo|first10=Manuela|last11=Gonzalez-de-Olano|first11=David|last12=Orfao|first12=Alberto|last13=Escribano|first13=Luis|title=Evaluation of the WHO criteria for the classification of patients with mastocytosis|journal=Modern Pathology|volume=24|issue=9|year=2011|pages=1157–1168|issn=0893-3952|doi=10.1038/modpathol.2011.84}}</ref><ref>{{cite book |author=Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates|title=Dacie & Lewis Practical Haematology |publisher=W B Saunders |location=London |year= |pages= |isbn=0-443-06377-X |pages=586}}</ref><ref name="O'Brien2004">{{cite journal|last1=O'Brien|first1=S.|title=Chronic Myelogenous Leukemia and Myeloproliferative Disease|journal=Hematology|volume=2004|issue=1|year=2004|pages=146–162|issn=1520-4391|doi=10.1182/asheducation-2004.1.146}}</ref><ref name="pmid23606974">{{cite journal| author=Murakami J, Shimizu Y| title=Hepatic manifestations in hematological disorders. | journal=Int J Hepatol | year= 2013 | volume= 2013 | issue= | pages= 484903 | pmid=23606974 | doi=10.1155/2013/484903 | pmc=PMC3626309 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23606974 }} </ref> | ||
*[[Complete blood count]] | *[[Complete blood count]] | ||
:*Increased [[granulocyte]]s of all types | :*Increased [[granulocyte]]s of all types | ||
:*Increased [[basophil]]s and [[eosinophil]]s | :*Increased [[basophil]]s and [[eosinophil]]s | ||
:*[[Thrombocytopenia]] | :*[[Thrombocytopenia]] or thrombocythemia | ||
:*[[Anemia]] | :*[[Anemia]] or [[polycythemia]] | ||
*Blood chemistry | *Blood chemistry | ||
:*The following blood levels may be elevated: | :*The following blood levels may be elevated: | ||
| Line 32: | Line 31: | ||
::*[[Aspartate transaminase]] (AST) | ::*[[Aspartate transaminase]] (AST) | ||
::*[[Uric acid]] | ::*[[Uric acid]] | ||
*Bleeding and clotting | *Bleeding and clotting factors | ||
:*The following blood | :*The following blood parameters may be elevated: | ||
::*[[Prothrombin time]] (PT) or [[international normalized ratio]] (INR) | ::*[[Prothrombin time]] (PT) or [[international normalized ratio]] (INR) | ||
::*[[Partial thromboplastin time]] (PTT) | ::*[[Partial thromboplastin time]] (PTT) | ||
*[[ | ::*[[D-dimer]] | ||
*[[Flow cytometry]] | *[[Flow cytometry]] | ||
:* Flow cytometry helps determine the type of cells that are present | :* Flow cytometry helps determine the type of cells that are present. | ||
*[[Cytogenetics]] | *[[Cytogenetics]] or [[karyotyping]] | ||
:*Chromosome changes that may occur in some people with leukemia include: | :*Chromosome changes that may occur in some people with leukemia include: | ||
::*[[Translocations]] | ::*[[Translocations]] | ||
::*Inversions | ::*[[Inversions]] | ||
::* | ::*Loss or gain of a chromosome | ||
*[[Fluorescent in situ hybridization]] (FISH) | *[[Fluorescent in situ hybridization]] (FISH) | ||
:*Similar to cytogenetics, but more specific | :*Similar to cytogenetics, but more specific for particular chromosomal translocations | ||
*Polymerase chain reaction | *Polymerase chain reaction | ||
:*Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample. | :*Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample. | ||
* Neutrophil alkaline phosphatase level | *Neutrophil alkaline phosphatase level | ||
* [[Vitamin B12]] (or B12 binding capacity) | *[[Vitamin B12]] (or B12 binding capacity) level | ||
*Erythropoietin level | |||
*Molecular testing for ''JAK2'', ''CALR'', and ''MPL'' mutations | |||
==Gallery== | ==Gallery== | ||
| Line 66: | Line 66: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
Latest revision as of 21:48, 21 June 2018
|
Myeloproliferative Neoplasm Microchapters |
|
Differentiating myeloproliferative neoplasm from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Myeloproliferative neoplasm laboratory findings On the Web |
|
American Roentgen Ray Society Images of Myeloproliferative neoplasm laboratory findings |
|
Directions to Hospitals Treating Myeloproliferative neoplasm |
|
Risk calculators and risk factors for Myeloproliferative neoplasm laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]
Overview
Laboratory findings associated with the diagnosis of myeloproliferative neoplasm include leukocytosis, thrombocytopenia, and anemia.
Laboratory Findings
Laboratory findings associated with myeloproliferative neoplasm include:[1][2][3][4][5][6]
- Increased granulocytes of all types
- Increased basophils and eosinophils
- Thrombocytopenia or thrombocythemia
- Anemia or polycythemia
- Blood chemistry
- The following blood levels may be elevated:
- Blood urea nitrogen (BUN)
- Creatinine
- Phosphate
- Lactate dehydrogenase (LDH)
- Alanine aminotransferase (ALT)
- Aspartate transaminase (AST)
- Uric acid
- Bleeding and clotting factors
- The following blood parameters may be elevated:
- Prothrombin time (PT) or international normalized ratio (INR)
- Partial thromboplastin time (PTT)
- D-dimer
- Flow cytometry helps determine the type of cells that are present.
- Chromosome changes that may occur in some people with leukemia include:
- Translocations
- Inversions
- Loss or gain of a chromosome
- Similar to cytogenetics, but more specific for particular chromosomal translocations
- Polymerase chain reaction
- Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample.
- Neutrophil alkaline phosphatase level
- Vitamin B12 (or B12 binding capacity) level
- Erythropoietin level
- Molecular testing for JAK2, CALR, and MPL mutations
Gallery
-
![Representative Philadelphia negative metaphase bone marrow cell with a t(9;12)(q34;p13) translocation. (a) G-banded karyotype; (b) FISH analysis demonstrates lack of BCR-ABL1 fusion but reveals a small third signal from the ABL1 probe (arrow) and; (c) The ETV6 split signal (arrowed in red) on der(9)t(9;12) from the break-apart FISH probe shows the gene rearrangement and confirms G banding results. The red/green fusion signal marks the normal gene.[7]](/images/b/ba/MPN-FISH.jpg)
Representative Philadelphia negative metaphase bone marrow cell with a t(9;12)(q34;p13) translocation. (a) G-banded karyotype; (b) FISH analysis demonstrates lack of BCR-ABL1 fusion but reveals a small third signal from the ABL1 probe (arrow) and; (c) The ETV6 split signal (arrowed in red) on der(9)t(9;12) from the break-apart FISH probe shows the gene rearrangement and confirms G banding results. The red/green fusion signal marks the normal gene.[7]
![Representative Philadelphia negative metaphase bone marrow cell with a t(9;12)(q34;p13) translocation. (a) G-banded karyotype; (b) FISH analysis demonstrates lack of BCR-ABL1 fusion but reveals a small third signal from the ABL1 probe (arrow) and; (c) The ETV6 split signal (arrowed in red) on der(9)t(9;12) from the break-apart FISH probe shows the gene rearrangement and confirms G banding results. The red/green fusion signal marks the normal gene.[7]](/index.php/File:MPN-FISH.jpg)
References
- ↑ Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab
- ↑ James W. Vardiman (2009). "Chronic myelogenous leukemia, BCR-ABL1+". American journal of clinical pathology. 132 (2): 250–260. doi:10.1309/AJCPUN89CXERVOVH. PMID 19605820. Unknown parameter
|month=ignored (help) - ↑ Sánchez-Muñoz, Laura; Alvarez-Twose, Ivan; García-Montero, Andrés C; Teodosio, Cristina; Jara-Acevedo, María; Pedreira, Carlos E; Matito, Almudena; Morgado, Jose Mario T; Sánchez, Maria Luz; Mollejo, Manuela; Gonzalez-de-Olano, David; Orfao, Alberto; Escribano, Luis (2011). "Evaluation of the WHO criteria for the classification of patients with mastocytosis". Modern Pathology. 24 (9): 1157–1168. doi:10.1038/modpathol.2011.84. ISSN 0893-3952.
- ↑ Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates. Dacie & Lewis Practical Haematology. London: W B Saunders. p. 586. ISBN 0-443-06377-X.
- ↑ O'Brien, S. (2004). "Chronic Myelogenous Leukemia and Myeloproliferative Disease". Hematology. 2004 (1): 146–162. doi:10.1182/asheducation-2004.1.146. ISSN 1520-4391.
- ↑ Murakami J, Shimizu Y (2013). "Hepatic manifestations in hematological disorders". Int J Hepatol. 2013: 484903. doi:10.1155/2013/484903. PMC 3626309. PMID 23606974.
- ↑ Gancheva, Katya; Virchis, Andres; Howard-Reeves, Julie; Cross, Nick CP; Brazma, Diana; Grace, Colin; Kotzampaltiris, Paul; Partheniou, Fedra; Nacheva, Elisabeth (2013). "Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review". Molecular Cytogenetics. 6 (1): 39. doi:10.1186/1755-8166-6-39. ISSN 1755-8166.